Ahmedabad: Torrent Pharmaceuticals Ltd reported a 9.6% year-on-year decline in consolidated net profit to Rs 534 crore for the second quarter of FY27, despite a 50.8% rise in revenue to Rs 4,979 crore.The company’s revenue growth indicated the inclusion of the JB business and stronger performance in its core markets. Operating EBITDA rose 53.8% to Rs 1,666 crore, while the operating EBITDA margin improved to 33.5% from 32.8% a year earlier.Torrent Pharma’s base business revenue grew 18% to Rs 3,893 crore, driven by branded formulations. India revenue rose 20% to Rs 2,181 crore, outpacing the Indian pharmaceutical market’s 12% growth, according to the PharmaTrac dataset cited by the company. The company reported a 32% market share for its generic semaglutide portfolio, combining oral and injectable products.Brazil revenue increased 38% to Rs 440 crore, while US revenue grew 24% to Rs 417 crore. Germany remained a weak market, with revenue declining 7% to Rs 283 crore amid supply disruptions at a third-party supplier and the loss of high-volume tenders.The JB business recorded revenue of Rs 1,086 crore during the quarter. Its integration following the merger, effective July 8, 2026, temporarily affected revenue. The company attributed the impact to integrating the India business, optimising its global business network, and aligning manufacturing and quality management systems.For the first half of FY27, consolidated revenue rose 52.8% to Rs 9,900 crore. Operating EBITDA increased 57.4% to Rs 3,330 crore. Net profit declined 3.4% to Rs 1,100 crore from Rs 1,139 crore in the corresponding period last year. Torrent Pharma shares closed at Rs 4,482 apiece on the BSE, down 2.78%, at market close on Friday.
